Market Currents
In a Phase 3 trial, rivaroxaban, a blood thinner from J&J (JNJ) and Bayer (BAYRY.PK), cut...
-
Monday, November 14, 2011, 3:31 AM ETIn a Phase 3 trial, rivaroxaban, a blood thinner from J&J (JNJ) and Bayer (BAYRY.PK), cut heart attacks, strokes, and cardiovascular deaths by 16% in patients who had suffered heart attacks or unstable chest pain. The drug is already used to prevent strokes, and approval for those with acute coronary syndrome could open up a $1B+ market. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
